Earnings call transcript: Perrigo Q2 2026 earnings beat lifts shares 25%

Perrigo shares jumped 25.14% in pre-market to $13.49 after Q2 2026 results, driven by adjusted EPS strength: core adjusted EPS was $0.46 vs. expectations (ahead despite sales weakness) and all-in adjusted diluted EPS was $0.50. Core net sales fell 3.1% YoY and core adjusted gross margin dropped 250 bps to 37% as retailer destocking and softer consumer demand offset growth in infant formula (+23% YoY). The company maintained its full-year 2026 outlook and updated the effective tax rate to ~18%, while also noting $80m-$100m of savings from its operational enhancement program by 2027 and a $359m Dermacosmetics sale used largely for debt reduction (cash from ops $83m; dividends $14m).

Analysis

The market is rewarding PRGO for a credibility reset, but the setup is still more about self-help than demand reacceleration. The quarter showed that operating leverage can work when service levels, mix and opex line up, yet a meaningful portion of the EPS upside came from transitory items and the business is still vulnerable to retailer inventory swings and seasonal normalization. That makes the current move feel ahead of the fundamental revision cycle unless H2 delivers clean organic growth and gross margin stabilization.

Second-order, the retailer relationship is the real asset. If PRGO can use private-label execution plus demand generation to grow category dollars, mass merchants like TGT can capture better OTC economics without taking on branded inventory risk, while branded OTC peers face more promotional pressure and shelf-space dilution. The infant-formula review is a longer-dated option value: any monetization would be leverage-positive and could re-rate the equity, but until there is a transaction it should be treated as optionality, not a base case.

The main risk to the rally is that investors confuse a better process with a better end-market. If category trends stall, retailer destocking persists, or the tariff/transition benefits roll off without true margin recovery, the stock can give back a lot of the gap over the next 1-2 quarters. The contrarian case is that e-commerce share gains and platform-based innovation may be underappreciated, but that should show up in the next two prints, not be assumed today.

Key Decisions for Investors

• Fade the premarket spike in PRGO tactically: initiate a small short or buy Sep/Oct put spreads after the gap if the stock holds above the open, with a stop if next-quarter organic sales turn positive and gross margin stabilizes.
• Do not chase the move on the long side until management proves H2 revenue inflects; wait for either a pullback back toward the pre-earnings range or a confirmed guide raise in the next print before building a core long.
• Watch TGT as a relative beneficiary of stronger private-label OTC penetration; if PRGO keeps gaining share without margin giveaways, TGT’s store-brand economics should improve over 1-3 quarters.
• Set a catalyst alert on the infant-formula review: any divestiture/partnering announcement is a leverage-reduction event that could justify a re-rating, but absent that, treat it as non-cash optionality.